208 related articles for article (PubMed ID: 25770994)
1. Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy.
Alferiev IS; Iyer R; Croucher JL; Adamo RF; Zhang K; Mangino JL; Kolla V; Fishbein I; Brodeur GM; Levy RJ; Chorny M
Biomaterials; 2015 May; 51():22-29. PubMed ID: 25770994
[TBL] [Abstract][Full Text] [Related]
2. Nanocarrier-Based Delivery of SN22 as a Tocopheryl Oxamate Prodrug Achieves Rapid Tumor Regression and Extends Survival in High-Risk Neuroblastoma Models.
Alferiev IS; Guerrero DT; Soberman D; Guan P; Nguyen F; Kolla V; Fishbein I; Pressly BB; Brodeur GM; Chorny M
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163672
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM
Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.
Nguyen F; Alferiev I; Guan P; Guerrero DT; Kolla V; Moorthy GS; Chorny M; Brodeur GM
Clin Cancer Res; 2018 Jun; 24(11):2585-2593. PubMed ID: 29514842
[No Abstract] [Full Text] [Related]
5. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
[TBL] [Abstract][Full Text] [Related]
6. Poloxamer-linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high-risk neuroblastoma with primary and acquired chemoresistance.
Alferiev IS; Guerrero DT; Guan P; Nguyen F; Kolla V; Soberman D; Pressly BB; Fishbein I; Brodeur GM; Chorny M
FASEB J; 2022 Mar; 36(3):e22213. PubMed ID: 35192728
[TBL] [Abstract][Full Text] [Related]
7. Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.
Monterrubio C; Paco S; Olaciregui NG; Pascual-Pasto G; Vila-Ubach M; Cuadrado-Vilanova M; Ferrandiz MM; Castillo-Ecija H; Glisoni R; Kuplennik N; Jungbluth A; de Torres C; Lavarino C; Cheung NKV; Mora J; Sosnik A; Carcaboso AM
J Control Release; 2017 Jun; 255():108-119. PubMed ID: 28412222
[TBL] [Abstract][Full Text] [Related]
8. Sub-100nm, long tumor retention SN-38-loaded photonic micelles for tri-modal cancer therapy.
Yang X; Xue X; Luo Y; Lin TY; Zhang H; Lac D; Xiao K; He Y; Jia B; Lam KS; Li Y
J Control Release; 2017 Sep; 261():297-306. PubMed ID: 28700898
[TBL] [Abstract][Full Text] [Related]
9. Sustained delivery of a camptothecin prodrug - CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity.
Dong D; Hsiao CH; Giovanella BC; Wang Y; Chow DS; Li Z
Int J Nanomedicine; 2019; 14():3799-3817. PubMed ID: 31213802
[No Abstract] [Full Text] [Related]
10. Encapsulation and Controlled Release of a Camptothecin Prodrug from Nanocarriers and Microgels: Tuning Release Rate with Nanocarrier Excipient Composition.
Wilson BK; Sinko PJ; Prud'homme RK
Mol Pharm; 2021 Mar; 18(3):1093-1101. PubMed ID: 33440941
[TBL] [Abstract][Full Text] [Related]
11. An activatable prodrug for the treatment of metastatic tumors.
Kim EJ; Bhuniya S; Lee H; Kim HM; Cheong C; Maiti S; Hong KS; Kim JS
J Am Chem Soc; 2014 Oct; 136(39):13888-94. PubMed ID: 25238144
[TBL] [Abstract][Full Text] [Related]
12. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Pastorino F; Loi M; Sapra P; Becherini P; Cilli M; Emionite L; Ribatti D; Greenberger LM; Horak ID; Ponzoni M
Clin Cancer Res; 2010 Oct; 16(19):4809-21. PubMed ID: 20702613
[TBL] [Abstract][Full Text] [Related]
13. Preparation of a camptothecin prodrug with glutathione-responsive disulfide linker for anticancer drug delivery.
Xu Z; Wang D; Xu S; Liu X; Zhang X; Zhang H
Chem Asian J; 2014 Jan; 9(1):199-205. PubMed ID: 24136878
[TBL] [Abstract][Full Text] [Related]
14. 10-Boronic acid substituted camptothecin as prodrug of SN-38.
Wang L; Xie S; Ma L; Chen Y; Lu W
Eur J Med Chem; 2016 Jun; 116():84-89. PubMed ID: 27060760
[TBL] [Abstract][Full Text] [Related]
15. Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity.
Duhem N; Danhier F; Pourcelle V; Schumers JM; Bertrand O; Leduff CS; Hoeppener S; Schubert US; Gohy JF; Marchand-Brynaert J; Préat V
Bioconjug Chem; 2014 Jan; 25(1):72-81. PubMed ID: 24328289
[TBL] [Abstract][Full Text] [Related]
16. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors.
Fang T; Dong Y; Zhang X; Xie K; Lin L; Wang H
Int J Pharm; 2016 Oct; 512(1):39-48. PubMed ID: 27544846
[TBL] [Abstract][Full Text] [Related]
17. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency.
Lin MH; Hung CF; Hsu CY; Lin ZC; Fang JY
Future Med Chem; 2019 Aug; 11(16):2131-2150. PubMed ID: 31538520
[TBL] [Abstract][Full Text] [Related]
18. Lipid prodrug nanocarriers in cancer therapy.
Mura S; Bui DT; Couvreur P; Nicolas J
J Control Release; 2015 Jun; 208():25-41. PubMed ID: 25617724
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation.
Lee P; Zhang R; Li V; Liu X; Sun RW; Che CM; Wong KK
Int J Nanomedicine; 2012; 7():731-7. PubMed ID: 22359452
[TBL] [Abstract][Full Text] [Related]
20. Vitamin E-based prodrug self-delivery for nanoformulated irinotecan with synergistic antitumor therapeutics.
Ling L; Ismail M; Shang Z; Hu Y; Li B
Int J Pharm; 2020 Mar; 577():119049. PubMed ID: 31982558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
